

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

1. (Currently amended) A solid pharmaceutical composition for oral administration comprising (2S)-2-amino-4-{{[2-(ethanimidoylamino)ethyl]thio}butanoic acid, a pharmaceutically acceptable bulking agent and one or more antioxidants or chelating agents, wherein the (2S)-2-amino-4-{{[2-(ethanimidoylamino)ethyl]thio}butanoic acid is in the form of its (1:1) compound with phosphoric acid, or a solvate thereof.
2. (Canceled).
3. (Previously presented) The pharmaceutical composition as claimed in claim 2 wherein the solvate is a hydrate.
4. (Previously presented) The pharmaceutical composition as claimed in claim 3 wherein the hydrate is the monohydrate.
5. (Previously presented) The pharmaceutical composition as claimed in claim 3 wherein the hydrate is the trihydrate.
6. (Previously presented) The pharmaceutical composition as claimed in claim 1 wherein the (2S)-2-amino-4-{{[2-(ethanimidoylamino)ethyl]thio}butanoic acid comprises from about 0.1 to about 5% by weight, the pharmaceutically acceptable bulking agent comprises from about 80 to about 99.5% by weight, and the antioxidant, chelating agent, or mixture thereof comprises from about 0.005 to about 5% by weight, based on the dry weight.
7. (Previously presented) The pharmaceutical composition as claimed in claim 1 wherein the antioxidants or chelating agents are selected from the group comprising EDTA, malic acid, ascorbic acid and mixtures thereof.

8. (Previously presented) The pharmaceutical composition as claimed in claim 1 wherein the pharmaceutically acceptable bulking agent comprises microcrystalline cellulose, starch or a mixture thereof.
9. (Previously presented) A method for the treatment of a clinical condition in a mammal, for which an inhibitor of nitric oxide synthase is indicated, which comprises administration of a pharmaceutical composition as claimed in claim 1.
10. (Previously presented) The method as claimed in claim 9 wherein the clinical condition is selected from the group consisting of arthritis, asthma, rhinitis, chronic obstructive pulmonary disease, ileus, migraine, pain and irritable bowel syndrome.
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Previously presented) The method as claimed in claim 9 wherein said mammal is a human.
17. (Canceled).